Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Coating Significantly Extends Longevity of Implantable Biosensors

By HospiMedica International staff writers
Posted on 14 Mar 2025

Wearable and implantable biosensors capable of accurately detecting biological molecules in a non-invasive or minimally invasive way offer enormous potential for monitoring patients’ health and their responses to treatments. More...

A notable example is wearable glucose monitors, which track blood glucose levels and convert the data into easily interpretable and continuously recorded electrical signals, playing a crucial role in managing diabetes. Similar biosensors have been designed to monitor electrolytes in sweat, biomarkers in interstitial fluid near the skin's surface, and to track the function of internal tissues. However, these implantable biosensors are limited in their utility due to a challenge known as "biofouling." Biofouling occurs when bacteria, human cells, or molecules from the body's biofluids accumulate on the sensor surface, interfering with the sensor’s ability to bind to its target molecule (analyte), disrupting its electrical signal generation. Additionally, implanted biosensors can trigger "foreign body responses," which activate pro-inflammatory immune cells and may lead to fibrotic tissue formation.

Overcoming these challenges would significantly enhance the potential of clinical diagnostics and research, enabling long-term monitoring for chronic or autoimmune diseases, assessing responses to existing and experimental therapies in clinical trials, and tracking physiological and pathological signals from organs such as the brain. To address this, a multidisciplinary team of researchers at the Wyss Institute for Biologically Inspired Engineering, Harvard University (Boston, MA, USA), has developed a novel coating technology that promises to greatly extend the lifespan of wearable and implanted biosensors while maintaining their electrical signal functionality. This new approach enables the continuous monitoring of analytes in various biofluids within the body, potentially for weeks at a time.

The new coating builds on the Wyss Institute's history of groundbreaking electrochemical biosensor technologies. The team demonstrated that when applied to electrochemical sensors, this coating prevented the growth of Pseudomonas aeruginosa, a bacterial species responsible for the formation of antibiotic-resistant biofilms on biosensors and other implants. Additionally, the coating stopped the adhesion of primary human fibroblasts and inhibited unwanted immune cell activation, all while preserving the sensor’s ability to detect key inflammatory proteins for over three weeks.

This coating consists of a cross-linked structure made from bovine serum albumin (BSA) and functionalized graphene. The graphene ensures efficient electrical signaling, while the BSA lattice forms a natural barrier that prevents the binding of various biological and molecular contaminants. This structure also allows for the stable incorporation of antibodies that detect specific analytes, as well as antibiotic drugs to combat biofouling. In a proof-of-concept study, the team successfully demonstrated the continuous and accurate detection of two key biomarkers of inflammation over more than three weeks using specially designed sensors exposed to complex human plasma.

During this period, the coating effectively resisted fibroblast cell attachment and the formation of biofilms typically created by P. aeruginosa, while also remaining undetected by pro-inflammatory immune cells. Furthermore, the coating can be produced from cost-effective components using a simple, scalable process, enabling large-scale production of in vivo biosensors. The Wyss Institute has patented this innovative coating technology and is actively seeking partners to help advance it toward real-world applications that can make a direct impact on patient care and scientific research.

“With this novel coating technology, which can offer durable protection of implantable biosensor devices, we have removed a central bottleneck in the development of next-generation electrochemical in vivo sensors. In the age of personalized medicine and digital health, it brings a plethora of diagnostic and research applications within reach,” said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who led the study.

Related Links:
Wyss Institute


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gold Member
Blood Gas Analyzer
i-Check200
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The study is the first to demonstrate a single nanomaterial platform that combines rapid blood clotting, activation of the body’s own latent growth factors, recruitment of bone-forming stem cells and enhanced bone regeneration. (Image Credit: Stef Zingsheim/University of Sydney)

Nanobone Material Activates Natural Repair Signals to Regrow Bone

Cleft lip and palate is a birth defect that affects about 1 in 700 children and occurs when parts of the upper lip or roof of the mouth do not fully fuse during pregnancy. Repairing the resulting jawbone... Read more

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.